NCT02183025

Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea

Double Blind Study to Evaluate Efficacy and Safety of Meloxicam 7.5 mg and 15 mg Versus Mefenamic Acid 1500 mg in the Treatment of Dysmenorrhea

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 337 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: Female
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

To access the efficacy and safety of Meloxicam 7.5 mg and 15 mg once daily compared with Mefenamic acid 500 mg t.i.d. over a treatment period of 3-5 days, during an observation period of 3 menstrual cycles, for the symptomatic relief of primary dysmenorrhea

Conditions

• Dysmenorrhea

Interventions

Type	Name	Description
DRUG	Meloxicam 7.5 mg
DRUG	Meloxicam 15 mg
DRUG	Mefenamic acid 500 mg
DRUG	Placebo matching 7.5 mg meloxicam
DRUG	Placebo matching 15 mg meloxicam
DRUG	Placebo matching 500 mg mefenamic acid

Timeline

• Start date: 1998-01-01
• Primary completion: 1999-04-01
• First posted: 2014-07-08
• Last updated: 2018-08-31